Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

VICC toll-free number 1-877-936-8422

Clinical Trials for Lung Cancers

32 Open Trials

Trial Type Protocol No. &
Open Date
Summary

Basic Science

Lung
Non Small Cell

VICCTHO0547

12/19/2005

Molecular Fingerprints in Lung Cancer: Predicting Tumor Response to Therapy (SPORE)

Basic Science

Lung
Non Small Cell
Small Cell

VICCTHO0398

12/04/2003

Molecular Predictors of Lung Cancer Behavior. (SPORE)

Basic Science

Lung
Non Small Cell

VICCTHO0136

05/01/2001

Molecular Fingerprinting of Lung Cancer (SPORE)

Diagnostic

Lung

VICCTHO1524

06/16/2015

PET Imaging of Lung Cancer and Indeterminate Pulmonary Nodules with 18F-FSPG

Diagnostic

Lung
Miscellaneous
Non Small Cell

VICCTHO1078

04/12/2011

Nashville Early Diagnosis Lung Cancer Project

Other

Lung

VICCTHO1496

04/03/2015

Lung Cancer Screening Program at VICC: Correlative Study

Other

Lung
Miscellaneous
Small Cell

VICCMD1494

10/31/2014

Specimen Collection under Clinical Protocol 06-C-0213 for Generation of Patient-Derived Models

Treatment

Lung
Small Cell

VICCTHO1510

07/09/2015

A Phase 2 Study of MM-121 in Combination with Docetaxel or Pemetrexed versus Docetaxel or Pemetrexed Alone in Patients with Heregulin Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Treatment

Lung

VICCTHN13108

05/22/2015

A Randomized Phase I/II Study of Nab-Paclitaxel, or Paclitaxel, Plus Carboplatin with Concurrent Radiation Therapy Followed by Consolidation in Patients with Favorable Prognosis Inoperable Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)

Treatment

Lung
Non Small Cell

VICCTHO1499

04/23/2015

TIGER 1: A Randomized, Open-Label, Phase II Study of CO-1686 or Erlotinib as First-Line Treatment of Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer (NSCLC)

Treatment

Lung
Non Small Cell

ECOGTHOS1400

04/02/2015

Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer

Treatment

Lung
Non Small Cell

VICCTHO1493

04/02/2015

Phase 1 Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-906024 in Subjects with Advanced Solid Tumors

Treatment

Lung
Non Small Cell

VICCTHO1443

03/11/2015

A Phase III, Randomized, Open-Label, Cross-Over, Multi-Center, Safety and Efficacy Study to Evaluate Nab-Paclitaxel (Abraxane?) as Maintenance Treatment after Induction with Nab-Paclitaxel Plus Carboplatin in Subjects with Squamous Cell Non-Small Cell Lung Cancer (NSCLC)

Treatment

Lung

CTSUTHOS1400

01/20/2015

Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer Lung-MAP Study Targeted Treatment for Advanced Squamous Cell Lung Cancer

Treatment

Lung
Non Small Cell

VICCTHO1478

11/14/2014

A Multi-arm, Phase Ib, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9291 in Combination with Ascending Doses of Novel Therapeutics in Patients with EGFRm+ Advanced NSCLC who have progressed following therapy with an EGFR TKI (TATTON)

Treatment

Esophageal
Head/Neck
Lung

VICCHN1464

11/14/2014

A Phase 2, Open-label Study of the Safety and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients with Advanced Squamous Cell Carcinoma of the Head and Neck, Lung or Esophagus.

Treatment

Lung

ECOGTHO2511-M

11/04/2014

Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination with Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer

Treatment

Lung
Non Small Cell

VICCTHO1467

10/02/2014

A Phase IIIb/IV Safety Trial of Nivolumab (BMS-936558) in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen

Treatment

Lung
Small Cell

VICCTHO1415

08/27/2014

A Randomized, Double-blind, Placebo-controlled, Phase 2 Clinical Trial of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)

Treatment

Lung
Non Small Cell

VICCTHN13111

08/27/2014

A Phase III, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial of Bavituximab Plus Docetaxel versus Docetaxel Alone in Patients with Previously Treated Stage IIIb/IV Non-Squamous Non-Small-Cell Lung Cancer

Treatment

Lung
Small Cell

VICCTHO1444

08/05/2014

A Randomized, Double Blind, Placebo-Controlled, Multicenter Phase II Study to Evaluate Efficacy and Safety of Roniciclib in Subjects with Extensive-Stage Disease Small Cell Lung Cancer (SCLC) Who are Receiving Cisplatin + Etoposide or Carboplatin + Etoposide as First-Line Therapy

Treatment

Lung
Non Small Cell

VICCTHO1429

08/05/2014

An Open-label, Phase 1 Dose Escalation Study of Oral ASP8273 in Subjects with Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations

Treatment

Lung

THOMK3475-024-M

08/05/2014

MK3475-024 A Randomized Open-Label Phase III Trial of Pembrolizumab versus Platinum based Chemotherapy in 1L Subjects with PD-L1 Strong Metastatic Non-Small Cell Lung Cancer

Treatment

Lung
Small Cell

VICCMD13112

05/19/2014

Phase IB Study of MK-3475 in Subjects with Select Advanced Solid Tumors

Treatment

Esophageal
Gastric/Gastroesophageal
Lung
Non Small Cell
Pancreatic

VICCPHI1360

04/22/2014

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination with Chemotherapy in Subjects with Advanced Solid Tumors

Treatment

Lung
Non Small Cell

VICCTHN1379

02/21/2014

A Phase III, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safety of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Combination with Docetaxel, in Patients receiving second line treatment for KRAS Mutation-Positive Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB/IV) (SELECT-1)

Treatment

Lung
Non Small Cell

VICCTHN1244

07/25/2012

Phase 1, First-in-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of X-396 in Patients with Advanced Solid Tumors

Treatment

Adrenocortical
Bladder
Breast
Cervical
Colon
Dermatologic
Esophageal
GIST
Gastric/Gastroesophageal
Gynecologic
Head/Neck
Kidney (Renal Cell)
Liver
Lung
Multiple Myeloma
Neuroendocrine
Non Small Cell
Ovarian
Pancreatic
Prostate
Rectal
Sarcoma
Uterine

VICCMD1188

06/08/2012

An Open-Label, Phase II Study of Vemurafenib in Patients with BRAF V600 Mutation-Positive Cancers

Treatment

Non Small Cell

ECOGTHO5508-M

02/09/2011

Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC

Treatment

Lung

ECOGTHO4508-M

12/07/2010

Three-Arm Randomized Phase II Study of Carboplatin and Paclitaxel in Combination with Cetuximab, IMC-A12 or Both for Advanced Non-small Cell Lung Cancer Patients WhoWill Not Receive Bevacizumab-based Therapy

Treatment

Lung

CTSUTHOC30607-M

02/17/2010

ARandomized, Phase III, Double-Blind Placebo-Controlled Trial of Sunitinib as Maintenance Therapy in Non-Progressing Patients following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced, Stage IIIB/IV Non-Small Cell Lung Cancer

Treatment

Non Small Cell

ECOGTHOE1505-M

07/27/2007

A Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumab for Patients with Completely Resected Stage IB (> or = 4 cm)- IIIA Non-Small Cell Lung Cancer (NSCLC)